Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Istodax on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Celgene Corporation (a Bristol Myers Squibb company)
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Istodax (romidepsin) is an infusion for cutaneous T-cell lymphoma (CTCL), a lymphoma that starts in T-cells and shows up mainly in the skin, as patches, plaques or tumours, and sometimes in the blood (Sézary syndrome) or lymph nodes. In the United States it is approved for adults with CTCL who have already had at least one systemic (whole-body) treatment.
An earlier US approval for peripheral T-cell lymphoma (PTCL) was withdrawn in 2021, so today Istodax is used for CTCL. It is given in hospital under a haematologist, oncologist or dermato-oncologist. See our blood cancer medicines.
Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs are enzymes that switch genes on and off. Blocking them changes how lymphoma cells read their genes, stopping their growth and causing them to die.
Istodax was tested in two studies with 167 CTCL patients in the US, Europe and Australia.
The dose is 14 mg/m² of body surface area, given as a 4-hour intravenous infusion on days 1, 8 and 15 of a 28-day cycle. Cycles are repeated as long as the patient benefits and tolerates it. For side effects, a dose may be delayed or lowered to 10 mg/m². Patients with moderate or severe liver problems start on a lower dose.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Istodax can lower platelets, white cells and red cells. Severe drops in lymphocytes, neutrophils, haemoglobin or platelets were among the common lab changes. Blood counts are checked regularly, and doses are delayed until they recover.
Serious and fatal infections, including pneumonia and sepsis, have occurred. Old viral infections such as hepatitis B and Epstein-Barr virus can flare up again. Patients who have had hepatitis B may need monitoring or preventive treatment. The risk may be higher in people who have had antibody treatments against lymphocytes.
ECG changes (ST-T wave changes) are common. Potassium and magnesium must be normal before each dose. People with congenital long QT syndrome, significant heart disease, or who take medicines that prolong the QT interval need heart monitoring.
When many lymphoma cells die quickly, salts released into the blood can harm the kidneys. People with advanced disease or a large tumour burden are watched closely.
Istodax can harm an unborn baby. Women who can become pregnant and men with female partners should use effective contraception during treatment and for 1 month after the last dose. It may make oestrogen-containing birth control pills less effective, so non-hormonal methods such as condoms or an IUD are advised. Do not breastfeed during treatment and for 1 week after the last dose.
Nausea, tiredness, infections, vomiting, loss of appetite, taste changes, constipation and itching. This is not a complete list.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Istodax is not sold in India, so it is imported for one named patient at a time. Each 28-day cycle has three infusions, so we plan the supply cycle by cycle.
Send the prescription with the patient's height and weight and the planned cycles. Each kit contains one 10 mg vial. For example, a patient with a body surface area of 1.7 m² needs about 24 mg per infusion, which is three kits per infusion and nine per cycle. Our pharmacist confirms the count.
A registered pharmacist checks the prescription, the skin or lymph node biopsy confirming CTCL, the list of earlier treatments and the patient's ID, and tells you at once if anything is missing.
The Istodax price in India is quoted for the kits needed per 28-day cycle, plus freight and customs clearance.
We prepare the Form 12A application to CDSCO under Rule 36 of the Drugs and Cosmetics Rules. CDSCO states the Form 12B permit is usually issued within one to two days and stays valid for six months.
Istodax kits are stored at 20°C to 25°C, so no fridge is needed, but they are protected from Indian summer heat in transit.
We deliver to the hospital pharmacy or day-care unit before the first infusion of each cycle.
The permit step usually takes one to two working days once all documents are complete. We share the expected delivery date with the quote, as it depends on stock at source and the flight route.
No. Istodax (romidepsin) has no marketing approval in India. An Indian company applied to make a generic romidepsin, but in May 2024 a CDSCO technical committee asked for a local Phase III trial first, and no approval appears in CDSCO's expert committee minutes up to November 2026. It can still be imported legally for a named patient under Rule 36, with a Form 12A application and a Form 12B permit.
Each Istodax kit has one 10 mg vial of romidepsin powder and one vial of special diluent (propylene glycol and alcohol). The hospital pharmacy dissolves the powder in this diluent, then dilutes it in saline for the 4-hour infusion. People often search for the romidepsin 10 mg price, but the cycle cost depends on body size.
Not from an open online store, because a medicine without Indian approval cannot be sold off the shelf. The legal way is to send the prescription to NPP, and we arrange the permit and import in the patient's name.
Patients from Nepal, Bangladesh, Bhutan, Sri Lanka and the Gulf can also ask us, subject to each country's import rules. Read our guide to Indian import regulations for the full legal process.
Istodax is made by Celgene, a Bristol Myers Squibb company. As an Istodax supplier in India under the named patient route, NPP buys it only through authorised channels and only after the patient's permit is issued, so every kit can be traced to one patient and one prescription.
Store the carton at 20°C to 25°C; short periods between 15°C and 30°C are allowed. Keep both vials (drug and diluent) in their carton. We ship in insulated packs that protect against heat; see our temperature-controlled shipping.
The label classes Istodax as a hazardous drug, so the hospital pharmacy follows special handling and disposal procedures when preparing it.
A registered pharmacist matches every order with the prescription and the permit before it leaves New Delhi.
For the Istodax cost in India and current availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Istodax is infused in hospital day-care units three times in each 28-day cycle, so we deliver to the treating hospital before each cycle.
See how we arrange delivery of imported medicines to hospitals across India.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message